Gilead Sciences (Nasdaq: GILD) plans to appeal against a federal jury’s decision to hand the company a record fine in a US patent infringement case.
The biotech company was found to have infringed the patent of fellow US company Merck & Co (NYSE: MRK) in its development of the big-selling hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir).
These drugs account for more than half of Gilead’s revenue and the judge in the case decided that 10% of its takings from the treatments were owed to Merck, so came to a figure for the royalties of $2.54 billion, reports Bloomberg in its coverage of the case.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze